Elayne Chan-Penebre

A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models

Elayne Chan-Penebre, Kristy G. Kuplast, Christina R. Majer et al. · Nature Chemical Biology · 2015 · 546 citations

Medicine, Medicinal Chemistry, Pharmacology +8

Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: <i>In Vitro</i> and <i>In Vivo</i> Preclinical Models

Elayne Chan-Penebre, Kelli Armstrong, Allison E. Drew et al. · Molecular Cancer Therapeutics · 2017 · 168 citations

Medicine, Molecular Biology, Oncology +17

Structure and Property Guided Design in the Identification of PRMT5 Tool Compound EPZ015666

Kenneth W. Duncan, Nathalie Rioux, P. Ann Boriack‐Sjodin et al. · ACS Medicinal Chemistry Letters · 2015 · 151 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15

EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL

Dorothy Brach, Danielle Johnston-Blackwell, Allison E. Drew et al. · Molecular Cancer Therapeutics · 2017 · 70 citations

Life Sciences, Oncology, Pharmacology +15

Species differences in metabolism of EPZ015666, an oxetane-containing protein arginine methyltransferase-5 (PRMT5) inhibitor

Nathalie Rioux, Kenneth W. Duncan, Ronald J. Lantz et al. · Xenobiotica · 2015 · 18 citations

Medicine, Biochemistry, Pharmacology +15